A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score assay in oestrogen receptor positive node negative breast cancer


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23611660

DOI
10.1016/j.ejca.2013.03.009

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Breast Neoplasms /diagnosis /drug therapy /economics /genetics; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Humans; Middle Aged; Neoplasm Staging; Prospective Studies; Receptors, Estrogen /biosynthesis; Risk Assessment; Risk Factors; Transcriptome; Young Adult

AccessionNumber
22013027548

Date bibliographic record published
26/07/2013